Immunomedics (NASDAQ:IMMU) announces encouraging Phase 1 data on antibody-drug conjugate Trodelvy (sacituzumab govitecan) (formerly IMMU-132) in patients with brain tumors. The results were virtually presented at ESMO.
At data cutoff, 19 patients were enrolled in the single-center study, 12 with recurrent glioblastoma multiforme (rGBM), the most aggressive type of brain cancer, and seven with brain metastatic breast cancer (BMBC).
Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38, the cytotoxic payload, for BMBC and rGBM, respectively, and produced partial responses in both cohorts.
Progression-free survival (ongoing) was 161-279 days in four BMBC patients and 7-315 days in six rGBM patients.
No new safety signals were observed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.